CN107106525B - 用于抑制单链rna病毒复制的治疗 - Google Patents

用于抑制单链rna病毒复制的治疗 Download PDF

Info

Publication number
CN107106525B
CN107106525B CN201580071321.3A CN201580071321A CN107106525B CN 107106525 B CN107106525 B CN 107106525B CN 201580071321 A CN201580071321 A CN 201580071321A CN 107106525 B CN107106525 B CN 107106525B
Authority
CN
China
Prior art keywords
virus
clarithromycin
rifabutin
alkyl
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580071321.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107106525A (zh
Inventor
列扎·法西
德罗尔·本-阿舍
盖伊·戈德堡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Redhill Biopharma Ltd
Original Assignee
Redhill Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redhill Biopharma Ltd filed Critical Redhill Biopharma Ltd
Priority to CN202110229970.9A priority Critical patent/CN112999222B/zh
Publication of CN107106525A publication Critical patent/CN107106525A/zh
Application granted granted Critical
Publication of CN107106525B publication Critical patent/CN107106525B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201580071321.3A 2014-10-24 2015-10-23 用于抑制单链rna病毒复制的治疗 Expired - Fee Related CN107106525B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110229970.9A CN112999222B (zh) 2014-10-24 2015-10-23 用于抑制单链rna病毒复制的治疗

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201462068492P 2014-10-24 2014-10-24
US201462068477P 2014-10-24 2014-10-24
US201462068469P 2014-10-24 2014-10-24
US201462068465P 2014-10-24 2014-10-24
US201462068487P 2014-10-24 2014-10-24
US62/068,487 2014-10-24
US62/068,465 2014-10-24
US62/068,469 2014-10-24
US62/068,492 2014-10-24
US62/068,477 2014-10-24
US201562188030P 2015-07-02 2015-07-02
US62/188,030 2015-07-02
PCT/IB2015/002173 WO2016063134A1 (en) 2014-10-24 2015-10-23 Therapy for inhibition of single-stranded rna virus replication

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110229970.9A Division CN112999222B (zh) 2014-10-24 2015-10-23 用于抑制单链rna病毒复制的治疗

Publications (2)

Publication Number Publication Date
CN107106525A CN107106525A (zh) 2017-08-29
CN107106525B true CN107106525B (zh) 2021-03-19

Family

ID=55760346

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110229970.9A Active CN112999222B (zh) 2014-10-24 2015-10-23 用于抑制单链rna病毒复制的治疗
CN201580071321.3A Expired - Fee Related CN107106525B (zh) 2014-10-24 2015-10-23 用于抑制单链rna病毒复制的治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110229970.9A Active CN112999222B (zh) 2014-10-24 2015-10-23 用于抑制单链rna病毒复制的治疗

Country Status (12)

Country Link
US (6) US9974800B2 (enExample)
EP (2) EP3209290A4 (enExample)
JP (1) JP6625631B2 (enExample)
KR (1) KR20170070234A (enExample)
CN (2) CN112999222B (enExample)
AU (2) AU2015334590B2 (enExample)
BR (1) BR112017008220A2 (enExample)
CA (1) CA2965258C (enExample)
IL (1) IL251847A0 (enExample)
MX (1) MX2017005350A (enExample)
SG (1) SG11201703307WA (enExample)
WO (1) WO2016063134A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9974800B2 (en) 2014-10-24 2018-05-22 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded RNA virus replication
MX382754B (es) * 2015-10-06 2025-03-13 Redhill Biopharma Ltd Terapias combinadas para tratar el cancer.
AU2017208970A1 (en) * 2016-01-18 2018-08-02 Arisan Therapeutics Adamatane derivatives for the treatment of filovirus infection
CN108853106B (zh) * 2017-05-09 2021-02-02 中国食品药品检定研究院 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
WO2020185637A1 (en) * 2019-03-08 2020-09-17 The Texas A&M University System Rose rosette virus infectious clones and uses thereof
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
WO2021181157A1 (en) * 2020-03-10 2021-09-16 Redhill Biopharma Ltd. Treatment of coronavirus infection
EP4142691A4 (en) * 2020-05-01 2024-05-15 MannKind Corporation COMPOSITION OF CLOFAZIMINE AND METHOD FOR TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS
EP3932409A1 (en) * 2020-06-29 2022-01-05 Consejo Superior de Investigaciones Científicas (CSIC) Compounds for the treatment and prevention of viral infections caused by coronaviruses
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
WO2025133697A2 (en) * 2023-12-20 2025-06-26 Redhill Biopharma Ltd. Combination therapy for inhibition of ebolavirus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335339B1 (en) * 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
WO2009106839A1 (en) * 2008-02-28 2009-09-03 Cambridge Enterprise Limited Use of tiamulin as an antiviral agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
HRP20010035A2 (en) 1998-07-15 2001-12-31 Hassan Jomaa Phosphorous organic compounds and their use
JP4733393B2 (ja) * 2002-11-18 2011-07-27 ポラリス・グループ インビボでウイルス複製を阻害する方法
US7132398B2 (en) * 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
CN101248041B (zh) * 2005-06-17 2013-11-20 艾宝奇生物工艺有限公司 鞘氨醇激酶抑制剂
KR101420094B1 (ko) * 2010-10-27 2014-07-17 (주)바이오니아 다양한 생체시료분석을 위한 전자동실시간정량증폭장비, 다양한 생체시료분석을 위한 자동정제 및 반응준비 장치, 전자동 핵산정제 및 실시간 정량 유전자증폭 방법, 전자동 핵산정제방법, 실시간정량ｐｃｒ을 이용한 병원균의 전자동 생균수검사방법, 정량면역ｐｃｒ을 이용한 전자동 항원농도획득방법 및 타겟항원에 라벨링된 부착용 타겟핵산의 정제방법
WO2012166859A2 (en) * 2011-06-01 2012-12-06 The Curators Of The University Of Missouri Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand rna virus infections
TWI573590B (zh) * 2011-09-20 2017-03-11 雷希爾生藥有限公司 治療自體免疫疾病之組成物及方法
US9974800B2 (en) * 2014-10-24 2018-05-22 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded RNA virus replication
MX382754B (es) * 2015-10-06 2025-03-13 Redhill Biopharma Ltd Terapias combinadas para tratar el cancer.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335339B1 (en) * 1998-01-13 2002-01-01 Scriptgen Pharmaceuticals, Inc. Triazine antiviral compounds
WO2009106839A1 (en) * 2008-02-28 2009-09-03 Cambridge Enterprise Limited Use of tiamulin as an antiviral agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
抗埃博拉病毒药物研究近期动态;杨臻峥等;《药学进展》;20140930;第38卷(第9期);第707-711页 *

Also Published As

Publication number Publication date
AU2019271958A1 (en) 2019-12-19
US20250325577A1 (en) 2025-10-23
CN112999222B (zh) 2024-05-28
EP3209290A4 (en) 2018-11-14
KR20170070234A (ko) 2017-06-21
US20240108643A1 (en) 2024-04-04
US9974800B2 (en) 2018-05-22
IL251847A0 (en) 2017-06-29
US11090325B2 (en) 2021-08-17
WO2016063134A1 (en) 2016-04-28
US20180318328A1 (en) 2018-11-08
US20210369754A1 (en) 2021-12-02
CA2965258C (en) 2023-09-19
US11786541B2 (en) 2023-10-17
BR112017008220A2 (pt) 2018-01-09
US10543222B2 (en) 2020-01-28
MX2017005350A (es) 2017-08-15
JP6625631B2 (ja) 2019-12-25
US20160113954A1 (en) 2016-04-28
CN107106525A (zh) 2017-08-29
AU2015334590B2 (en) 2019-08-29
JP2017531673A (ja) 2017-10-26
AU2015334590A1 (en) 2017-05-18
EP4134076A1 (en) 2023-02-15
CA2965258A1 (en) 2016-04-28
SG11201703307WA (en) 2017-05-30
US20200155585A1 (en) 2020-05-21
AU2019271958B2 (en) 2020-03-05
CN112999222A (zh) 2021-06-22
EP3209290A1 (en) 2017-08-30
US12370206B2 (en) 2025-07-29

Similar Documents

Publication Publication Date Title
CN107106525B (zh) 用于抑制单链rna病毒复制的治疗
EP3900717B1 (en) Vidofludimus for use in the treatment or prevention of viral diseases
CN111991401A (zh) 一种化合物在治疗SARS-CoV-2感染中的应用
IL237119A (en) Heterocyclic carboxamides for the treatment of viral diseases
HK1237643A1 (en) Therapy for inhibition of single-stranded rna virus replication
HK1237643B (zh) 用於抑制单链rna病毒复制的治疗
CN115708833A (zh) 吉西他滨在制备抗肝包虫药物中的应用
WO2025133697A2 (en) Combination therapy for inhibition of ebolavirus
CN101480391B (zh) 槐果碱在制备治疗由柯萨奇a病毒所引起疾病的药物中的应用
HK40062780A (en) Vidofludimus for use in the treatment or prevention of viral diseases
CN117838698A (zh) 奥拉替尼在制备治疗流感病毒感染的药物中的应用
CN117838689A (zh) 培菲替尼在制备治疗流感病毒感染的药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1237643

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210319